NVNO
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
enVVeno Medical Corporation (NVNO) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D+). The rating has held at C+ for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B+ (3.7) | B- (2.9) | C- (1.9) | D+ (1.5) | C+ (2.6) | C+ (2.5) |
| 2026-11-06 | B+ (3.8) | B- (2.9) | C- (1.9) | D+ (1.8) | C+ (2.7) | C+ (2.6) |
| 2026-10-30 | B+ (3.6) | B- (2.9) | C- (2.0) | D+ (1.6) | C+ (2.7) | C+ (2.5) |
| 2026-10-23 | B+ (3.6) | C+ (2.8) | C- (1.9) | D (1.4) | C+ (2.6) | C (2.5) |
| 2026-10-16 | B+ (3.7) | C+ (2.8) | C- (1.9) | D+ (1.7) | C+ (2.6) | C+ (2.6) |